ASPIRE BIOPHARMA HOLDINGS INC (ASBP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.87-4.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ASBP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of — · Company calendar date is not available
ASBP — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-08-10
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth under
Why it matters: Closing this deal would bring in more money and help Aspire grow. It could raise earnings and cash flow a lot.
Supportive ifThe acquisition of DCS is completed and announced by the end of Q3 2026.
Worry ifThe deal does not close because of unmet conditions or problems with due diligence.
Why it matters: Raising capital can make Aspire Biopharma stronger. This helps fund their growth.
Supportive ifA press release shows the Series A placement is done with strong interest from investors.
Worry ifNot getting the placement or having low investor interest is a worry.
Why it matters: Doing well with DCS is important for making more money from the purchase.
Supportive ifDCS achieves revenue growth of over 10% in the first full quarter post-acquisition.
Worry ifDCS revenue declines or fails to grow in the first full quarter after the acquisition.
Why it matters: Cutting debt can make finances better. It can also boost investor trust.
Supportive ifThe company has reduced its debt through exchange deals.
Worry ifNo progress on debt reduction, or an increase in total debt.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$420 on $10,000 · ±4.2% | How much price usually moves either way. |
| Bad day | $1,929 loss on $10,000 · 19.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,924 loss on $10,000 · 99.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Cutting debt can help financial health and boost investor confidence. It is key for the future.
Supportive ifAn announcement shows deals that greatly reduce debt.
Worry ifNo progress on debt reduction or further delays in negotiations.
Why it matters: This report will show revenue growth. It will also explain how the DCS acquisition affects Aspire's finances.
Watch forThe earnings report shows revenue growth above expectations. This means DCS is integrating well.
Also watch forThe earnings report shows revenue decline or lower growth. This raises concerns about the acquisition.
Why it matters: Finalizing this credit deal is key for funding the DCS acquisition without new equity. It impacts Aspire's financial health.
Supportive ifThe final terms of the credit deal are completed and made public.
Worry ifThe credit deal is not finished or the terms are bad, needing new equity.
Why it matters: Progress on this M&A could signal further growth and diversification for Aspire.
Watch forAspire has a deal to acquire FireFish TopCo, LLC.
Also watch forNo new updates or progress on acquiring FireFish TopCo, LLC.
Why it matters: This funding could help strengthen the balance sheet and support growth initiatives. Investors will be focused on the outcome.
Watch forAll 25,000 shares of Series A Convertible Preferred Stock were sold.
Also watch forNot placing the shares or a big drop in investor interest.
Why it matters: Finalizing the credit facility helps fund the DCS acquisition. This means no new equity is needed.
Supportive ifThe Aspire Credit Facility is finalized. It has good terms for the acquisition.
Worry ifThe credit facility terms are not good or it is not finalized.
Why it matters: Closing the acquisition will help Aspire earn more money. It is an important step for growth.
Supportive ifThe acquisition will close in Q3 2026 as planned. It meets all usual conditions.
Worry ifThe acquisition fails to close or faces significant delays beyond Q3 2026.
Why it matters: This capital raise helps with working capital and the DCS acquisition. Using it well could boost Aspire's growth.
Watch forAspire plans to improve operations or grow. They will use money from the capital raise.
Also watch forAspire does not improve operations or growth. This is true even after raising capital.
Why it matters: This credit facility helps fund the DCS deal. It does this without new equity.
Supportive ifThe credit facility is ready, and money is given for the DCS deal.
Worry ifIf the credit facility does not close or is late, it will hurt the deal.